^
    1d
    Moderate-Dose Local Radiotherapy in Symptomatic CD30-Positive, Anaplastic Lymphoma Kinase (ALK)-Negative Primary Cutaneous T-cell Lymphoma. (PubMed, Cureus)
    Localized radiotherapy was then administered, which resulted in progressive improvement of the lesion from the first sessions, with tumor volume reduction, decreased exudate, and partial re-epithelialization of the ulcerated bed. This case highlights the role of localized radiotherapy as an effective palliative and disease-controlling modality for cutaneous CD30+ T-cell lymphoma, particularly in symptomatic or treatment-refractory lesions.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • TNFRSF8 positive • TNFRSF8 expression • ALK negative
    6d
    Primary Cutaneous ALK-Negative Anaplastic Large Cell Lymphoma in a Filipino Male: Successful Treatment With Gemcitabine and Radiotherapy. (PubMed, Australas J Dermatol)
    Complete clinical response was achieved with no recurrence at 18 months follow-up. This case highlights combined gemcitabine and radiotherapy as an effective alternative in selected high-risk pcALCL patients, demonstrating durable disease control.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive • ALK negative
    |
    gemcitabine
    8d
    A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) (clinicaltrials.gov)
    P1/2, N=85, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK negative
    |
    golcadomide (CC-99282)
    18d
    Comparative Efficacy and Safety of First-Line Immune Checkpoint Inhibitors Plus Chemotherapy with or Without Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Carcinoma. (PubMed, Curr Oncol)
    Although PFS benefits were observed in certain subgroups, these were accompanied by significantly increased treatment-related toxicities. Our findings suggest that no clear subgroup has been identified where the benefit outweighs the risks, necessitating extreme clinical caution.
    Clinical • Retrospective data • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • PD-L1 negative • ALK negative
    |
    Avastin (bevacizumab)
    28d
    Research Progress in ALK+/- Anaplastic Large Cell Lymphoma--Review (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    Understanding the subtypes and molecular characteristics of ALCL is essential for optimizing therapeutic strategies. Therefore, this review summarizes recent research advances on ALK +/- ALCL to provide insights for optimizing treatment approaches.
    Review • Journal
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8) • TP63 (Tumor protein 63) • DUSP22 (Dual Specificity Phosphatase 22) • USP22 (Ubiquitin Specific Peptidase 22)
    |
    ALK positive • TNFRSF8 positive • ALK negative
    30d
    UMG1 Defines a Targetable Subset of T-Cell Lymphomas and Enables Precision Immunotherapy With a First-in-Class CD3ε Bispecific Engager. (PubMed, Hematol Oncol)
    Our findings suggest that the UMG1/CD3ε-BTCE selectively exerts potent anti-tumor activity against a relevant subset of TCLs. These findings support the development of a precision immunotherapy approach for patients with UMG1-expressing aggressive hematologic malignancies.
    Journal • IO biomarker
    |
    ALK (Anaplastic lymphoma kinase) • SPN (Sialophorin)
    |
    ALK negative
    |
    Zolinza (vorinostat)
    1m
    T-START-NR: T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR (clinicaltrials.gov)
    P=N/A, N=58, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New trial
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    ALK negative
    1m
    FIL_BREAL: BV-CHP Real-life and Biological Evidences in Patients With sALCL (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Fondazione Italiana Linfomi - ETS
    New trial
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK negative
    1m
    Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: Feb 2026 --> Feb 2027
    Trial initiation date
    |
    ALK (Anaplastic lymphoma kinase) • CD5 (CD5 Molecule) • DUSP22 (Dual Specificity Phosphatase 22) • USP22 (Ubiquitin Specific Peptidase 22)
    |
    ALK negative
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV